NCT06332079 2026-01-05
HAITI
Gruppo Oncologico del Nord-Ovest
Phase 2 Terminated
Clinical Trials
12 trialsNCT05553522 2025-12-31
Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer
Baptist Health South Florida
Phase 1 Terminated
NCT05417386 2025-11-18
FOLFIRINOX + NIS793 in Pancreatic Cancer
Massachusetts General Hospital
Phase 1 Terminated
NCT04363801 2025-10-09
DisTinGuish
Leap Therapeutics, Inc.
Phase 2 Terminated
NCT04701281 2025-09-18
SYS-CAPLIOX
AllVascular
Phase 1/2 Terminated
NCT07166367 2025-09-10
Phase II Study to Assess the Efficacy of ASLAN001 Plus Capecitabine in CNS Metastases for HER2+ Breast Cancer
National Cancer Centre, Singapore
Phase 2 Terminated
NCT03501979 2025-08-29
Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD
University of Alabama at Birmingham
Phase 2 Terminated
NCT03153280 2025-07-08
Lithium
Cancer Trials Ireland
Phase 1 Terminated
NCT07012330 2025-06-10
Comparing 177Lu-Dotatate/Capecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor Patients
Erasmus Medical Center
Phase 2 Terminated
NCT02420509 2025-06-04
Postoperative Chemotherapy in High-Grade Appendiceal Adenocarcinoma With Peritoneal Carcinomatosis
University of California, San Diego
Terminated
NCT04849364 2025-05-31
PERSEVERE
Hoosier Cancer Research Network
Phase 2 Terminated
NCT05336721 2025-03-24
A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC
Chipscreen Biosciences, Ltd.
Phase 2 Terminated